Antibody for ADCC And Inducing Cytokine Production
AssigneeLfb Biotechnologies
InventorsChristophe de ROMEUF, Arnaud GLACET, Jacques LIROCHON, Dominique BOUREL
Life of this patent
Estimating the term…
Abstract
The invention concerns chimeric monoclonal antibodies, humanized or human produced in selected cell lines, said antibodies exhibiting high affinity for the CD16 receptor of effector cells of the immune system and hence capable of inducing high ADCC, but also the property of inducing cytokine and interleukin secretion, in particular IFNγ, which can enhance the ADCC activity of effector cells and hence be used for treating cancers and infections by pathogenic agents.
Claims21
A human or humanized chimeric monoclonal antibody produced in a cell line selected for its properties of particular glycosylation of the Fc fragment of an antibody, or the glycan structure of which has been modified ex vivo, said antibody having an FcyRIII (CD16) -type ADCC rate of greater than 60%, 70%, 80% or preferably greater than 90%, compared with the same antibody produced in a CHO line or with a commercially available homologous antibody, characterized in that it has an ability to induce a rate of production of at least one cytokine by the Jurkat CD16 cell or a CD16 receptor-expressing effector cell of the immune system of greater than 60%, 100%, or preferably greater than 200%, compared with the same antibody produced in a CHO line or with a commercially available homologous antibody, and wherein said human, humanized, or chimeric monoclonal antibody is an anti-HLA-DR antibody.
Dependencies are inferred from the claim text.